Search - tctmd.com

Displaying 521 - 540 of 1616

Sort: Relevancy | Date

News Daily News

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

Shelley Wood

May 29, 2020

News Daily News

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Yael L. Maxwell

May 21, 2020

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

Shelley Wood

April 29, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

Michael O'Riordan

April 17, 2020

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

Todd Neale

April 03, 2020

News Features

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Shelley Wood

April 02, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

Shelley Wood

March 29, 2020

Advertisement

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

No Worse COVID-19 Prognosis With ACE Inhibitors, ARBs: ‘Living’ Review Suggests

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Dire, Unusual STEMI Complications Blamed on COVID-19 Hospital Avoidance

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content